

September 1, 2021

To,
The Company Secretary,
Beta Drugs Limited
1101, 11th Floor, Peninsula Park,
Fun Republic Lane, Link Road Andheri West,
Mumbai - 400053.

Dear Sir/ Madam,

Sub.: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Scrip Symbol: BETA

Pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find enclosed herewith the disclosure of change in shareholding of more than 2% in the prescribed format.

Please note that the acquirer along with persons acting in concert with him held 970044 (representing 10.09% of the paid up equity share capital of the company) equity shares of the company prior to current acquisition instead of 1006044 equity shares as shown inadvertently in our earlier disclosure dated February 3, 2020 due to oversight. Please note that we have not sold any shares during the said period.

Kindly take the above on record and acknowledge.



Ashish R Kacholia
Acquirer

Place: Mumbai

Encl.: Statement of Disclosure under Regulation 29(2)

C.C. To:

1. The Secretary,

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,

Bandra Kurla Complex, Bandra (East),

Mumbai 400051

Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Beta Drugs Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: Ashish R Kacholia PAC: M/s. Survavanshi Commtrade Private Limited		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights [#]	970044	10.09%	10.09%
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	970044	10.09%	10.09%
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	195200	2.03%	2.03%
b) VRs acquired /sold otherwise than by shares	-	-	-
Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-	-	-
d) Shares encumbered / invoked/released by the acquirer	-	-	-
e) Total (a+b+c+/-d)	195200	2.03%	2.03%

After the acquisition/sale, holding of:			
a) Shares carrying voting rights	1165244	12.12%	12.12%
b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
e) Total (a+b+c+d)	1165244	12.12%	12.12%
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market Acquisition		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	Various dated from 04.02.2020 to 30.08.2021		
Equity share capital / total voting capital of the TC before the said acquisition / sale*	9613790 Equity Shares of the face value of Rs. 10/- each aggregating Rs. 9,61,37,900/-		
Equity share capital/ total voting capital of the TC after the said acquisition / sale*	9613790 Equity Shares of the face value of Rs. 10/- each aggregating Rs. 9,61,37,900/-		
Total diluted share/voting capital of the TC after the said acquisition**	9613790 Equity Shares of the face value of Rs. 10/- each aggregating Rs. 9,61,37,900/-		

(#) The acquirer along with persons acting in concert with him held 970044 (representing 10.09% of the paid up equity share capital of the company) equity shares of the company prior to current acquisition instead of 1006044 equity shares as shown inadvertently in our earlier disclosure dated February 3, 2020 due to oversight.

(*) Total share capital/ voting capital taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants, if any into equity shares of the TC.



Ashish R Kacholia

Acquirer

Place: Mumbai

Date: September 1, 2021

September 1, 2021

To,
The Company Secretary,
Beta Drugs Limited
1101, 11th Floor, Peninsula Park,
Fun Republic Lane, Link Road Andheri West,
Mumbai - 400053.

Dear Sir/ Madam,

Sub.: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Scrip Symbol: **BETA**

Pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, please find enclosed herewith the disclosure of change in shareholding of more than 2% in the prescribed format.

Please note that the acquirer along with persons acting in concert with him held 970044 (representing 10.09% of the paid up equity share capital of the company) equity shares of the company prior to current acquisition instead of 1006044 equity shares as shown inadvertently in our earlier disclosure dated February 3, 2020 due to oversight. Please note that we have not sold any shares during the said period.

Kindly take the above on record and acknowledge.



Ashish R Kacholia
Acquirer

Place: Mumbai
Encl.: Statement of Disclosure under Regulation 29(2)

C.C. To:

1. The Secretary,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (East),
Mumbai 400051

Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Beta Drugs Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: Ashish R Kacholia PAC: M/s. Survavanshi Commtrade Private Limited		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights [#]	970044	10.09%	10.09%
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	970044	10.09%	10.09%
Details of acquisition/sale			
a) Shares carrying voting rights acquired/sold	195200	2.03%	2.03%
b) VRs acquired /sold otherwise than by shares	-	-	-
Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	-	-	-
d) Shares encumbered / invoked/released by the acquirer	-	-	-
e) Total (a+b+c+/-d)	195200	2.03%	2.03%

After the acquisition/sale, holding of:			
a) Shares carrying voting rights	1165244	12.12%	12.12%
b) Shares encumbered with the acquirer	-	-	-
c) VRs otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	-	-	-
e) Total (a+b+c+d)	1165244	12.12%	12.12%
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Open Market Acquisition		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	Various dated from 04.02.2020 to 30.082021		
Equity share capital / total voting capital of the TC before the said acquisition / sale*	9613790 Equity Shares of the face value of Rs. 10/- each aggregating Rs. 9,61,37,900/-		
Equity share capital/ total voting capital of the TC after the said acquisition / sale*	9613790 Equity Shares of the face value of Rs. 10/- each aggregating Rs. 9,61,37,900/-		
Total diluted share/voting capital of the TC after the said acquisition**	9613790 Equity Shares of the face value of Rs. 10/- each aggregating Rs. 9,61,37,900/-		

(#) The acquirer along with persons acting in concert with him held 970044 (representing 10.09% of the paid up equity share capital of the company) equity shares of the company prior to current acquisition instead of 1006044 equity shares as shown inadvertently in our earlier disclosure dated February 3, 2020 due to oversight.

(*) Total share capital/ voting capital taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants, if any into equity shares of the TC.



Ashish R Kacholia

Acquirer

Place: Mumbai

Date: September 1, 2021